Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy

Journal of Clinical Virology

Volumn 30, Issue 1, 2004, Pages 24-31

  Machado, Elizabeth S ^a   Lambert, John S ^b   Watson, Douglas C ^c   Afonso, Adriana O ^a   Da Cunha, Silvia M ^a   Nogueira, Susie A ^a   Caride, Elena ^a   Oliveira, Ricardo H ^a   Sill, Anne M ^b   DeVico, Anthony ^b   Tanuri, Amilcar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

^c UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Combination therapy; Genotypic resistance; HIV 1 subtype

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADOLESCENT; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; BRAZIL; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RATE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS TYPING;

ADOLESCENT; ANTI-HIV AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DNA, COMPLEMENTARY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RNA, VIRAL; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIREMIA;

EID: 11144357930     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2003.08.001     Document Type: Article

References (35)

1. Caride E., Brindeiro R., Hertogs K.et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and Non-B subtypes (F and A) of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virology. 275:2000;107-115.
2. Cohen Stuart J.W., Slieker W.A., Rijkers G.T.et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS. 12:1998;2155-2159.
3. Colgrove R.C., Pitt J., Chung P.H.et al. Selective vertical transmission of HIV antiretroviral resistance mutations. AIDS. 12:1998;2281-2288.
4. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistant mutation in HIV-1. International AIDS Society - USA. Topics in HIV medicine. vol. 11 (3), May/June 2003. Available at: http://www.iasusa.org.
5. de Martino M., Tovo P.A., Balducci M.et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV infection in children and the Italian National AIDS Registry. JAMA. 284:2000;190-197.
6. Dumans A.T., Soares M.A., Pieniazek D.et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother. 46:2002;3075-3079.
7. Eshleman S.H., Krogstad P., Jackson J.B.et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse- transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (PACTG 377). J. Infect. Dis. 183:2001;1732-1738.
8. Essajee S.M., Kim M., Gonzalez C.et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 13:1999;2523-2532.
9. Gibb D.M., Newberry A., Klein N.et al. Immune repopulation after HAART in previously untreated HIV-1 infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet. 355:2000;1331-1332.
10. Gortmaker S, Hughes M, Oyomopito R, et al. Impact of introduction of protease inhibitor therapy on reduction in mortality among children and youth infected with HIV. In: Proceedings of the 7th Conference on Retrovirus and Opportunistic Infections, San Francisco, CA; 2000 [Abstract 691].
11. Hejdeman B., Lenkei R., Leandersson A.C.et al. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res. Hum. Retroviruses. 17:2001;277-286.
12. Izopet J., Massip P., Souyris C.et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 14:2000;2247-2255.
13. Jankelevich S., Mueller B.U., Mackall C.L.et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J. Infect. Dis. 183:2001;1116-1120.
14. Kamkamidze G., Sullivan T., Charbonneau T. Occurence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants. J. Clin. Virol. 22:2001;143-148.
15. Kline M.W., Van Dyke R.B., Lindsey J.C.et al. Combination therapy with stavudine (d4T) plus didanosine (ddi) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. Pediatrics. 103:1999;e62.
16. Kumar S, Tamura K, Jakobsen IB, et al. MEGA2: Molecular Evolutionary Genetics Analysis software, Arizona State University, Tempe, AZ, USA; 2001.
17. Linde R., Funk M.B., Schuster T.et al. Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. AIDS. 15:2001;1077-1079.
18. Lole K.S., Bollinger R.C., Paranjape R.S.et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 73:1999;152-160.
19. Mellado M.J., Cilleruelo M.J., Ortiz M.et al. Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 16:1997;1032-1037.
20. Ministério da Saúde, Secretaria de Políticas de Saúde, Coordenação Nacional de DST e AIDS. Brasília, 2002. Guia de Tratamento Clínico da Infecção pelo HIV em crianças. Available at: http://www.aids.gov.br.
21. Morgado M.G., Sabino E.C., Shpaer E.G.et al. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res. Hum. Retroviruses. 10:1994;569-576.
22. Nachman A.S., Stanley K., Yogev R.et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. PACTG 339 Study Team. JAMA. 283:2000;492-498.
23. Nadal D., Steiner F., Cheseaux J.J. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Infection. 28:2000;287-296.
24. Palumbo P.E., Raskino C., Fiscus S.et al. Virologic and Immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human Immunodeficiency virus-infected infants and children. J. Infect. Dis. 179:1999;576-583.
25. Paterson D.L., Swindells S., Mohr J.et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV-1 infection. Ann. Intern. Med. 133:2000;21-30.
26. Perno C.F., Cozzi-Lepri A., Balotta C.et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naïve patients treated with protease inhibitor-based therapy. J. Infect. Dis. 15:2001;983-991.
27. Principi N., Marchisio P., De Pasquale M.P.et al. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res. Hum. Retroviruses. 10:1994;721-726.
28. Purswani M., Johann-Liang R., Cervia J., Noel G.J. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Pediatr. Infect. Dis. J. 18:1999;512-516.
29. Ramos A., Tanuri A., Schechter M.et al. Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg. Infect. Dis. 5:1999;65-74.
30. Renjifo B., Gilbert P., Chaplin B.et al. Emerging recombinant human immunodeficiency viruses: uneven representation of the envelope V3 region. AIDS. 13:1999;1613-1621.
31. Sabino E.C., Diaz R.S., Brigido L.F.et al. Distribution of HIV-1 subtypes seen in an AIDS clinic in São Paulo City, Brazil. AIDS. 10:1996;1579-1584.
32. Tanuri A., Swanson P., Devere S.et al. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J. Acquir. Immune Def. Syndr. Hum. Retrovirol. 20:1999a;60-66.
33. Tanuri A., Vicente A.C., Otsuki K.et al. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob. Agents Chemother. 43:1999b;253-258.
34. Thompson J.D., Higgins D.G., Gibson T.J. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673-4680.
35. Watson D.C., Farley J.J. Efficacy of and adherence to highly antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. 18:1999;682-689.